Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II PET imaging of MMR-expressing macrophages with 68Ga-NOTA-Anti-MMR-VHH2
2020-002483-31Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Sep 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NOTA-anti-MMR VHH2 in head and neck cancer (HNC), atherosclerosis, sarcoidosis and 1 more, sponsored by UZ Brussel. Primary endpoints: Correlation of 68Ga-NOTA-Anti-MMR-VHH2 uptake with therapeutic tumour response (Cohorts 1 and 2) and Proportion of head and neck malignancy patients with PET/CT uptake (Cohort 1). Started Sep 2020; status: completed.
02
Drugs
68Ga-NOTA-anti-MMR VHH2
03
Conditions
head and neck cancer (HNC)atherosclerosissarcoidosishaemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2020-002483-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002483-31.